Clark Schneider Kelli M, Banks Peter M, Collie Angela M B, Lanigan Christopher P, Manilich Elena, Durkin Lisa M, Hill Brian T, Hsi Eric D
a Cleveland Clinic , Cleveland , OH , USA ;
b Ventana Medical Systems, Inc., Roche Group , Tucson , AZ , USA ;
Leuk Lymphoma. 2016 Jul;57(7):1640-8. doi: 10.3109/10428194.2015.1101099. Epub 2015 Dec 23.
Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evaluated for MYC and BCL2 protein expression using various cut-offs that have been recommended in prior studies. Independent of the International Prognostic Index risk group, cases with dual protein expression of BCL2 and MYC using ≥50%/40% cut-offs and ≥70%/40% had significantly shorter overall survival than cases without. It was verified in this patient population that the use of BCL2 and MYC immunohistochemistry, performed with available in vitro diagnostic-cleared antibodies, provides rapid prognostic information in patients with de novo diffuse large B-cell lymphoma. This study has practical implications for diagnostic laboratories and serves as a guide for implementation in the setting of future clinical trials.
近期研究表明，MYC和BCL2蛋白共表达是弥漫性大B细胞淋巴瘤预后不良的独立指标。然而，双表达染色的免疫组织化学方案及评分临界值因研究而异。采用先前研究中推荐的各种临界值，对69例弥漫性大B细胞淋巴瘤患者的MYC和BCL2蛋白表达进行了评估。独立于国际预后指数风险组，使用≥50%/40%临界值和≥70%/40%临界值的BCL2和MYC双蛋白表达病例的总生存期显著短于无双蛋白表达的病例。在该患者群体中得到验证的是，使用经体外诊断批准的抗体进行BCL2和MYC免疫组织化学检测，可为初发性弥漫性大B细胞淋巴瘤患者提供快速的预后信息。本研究对诊断实验室具有实际意义，并可为未来临床试验的实施提供指导。
Zotero 插件